Join Leading Translational Scientists and Executive Leaders in Oncology, AI, and Informatics for the 26th Cancer Centers Symposium in Baltimore this Fall
HOTEL DEADLINE: Four Seasons Baltimore
Register for the 26th Cancer Center Data and AI Symposium chaired by @hopkinskimmel & @umms November 6-7
https://t.co/wTHGyNEcIi
The highly anticipated #ASTRO26 Clinical Trials Session showcased important new evidence and emerging advances across radiation medicine, highlighting findings with meaningful implications for clinical practice.
Start planning your schedule for Day 3: https://t.co/dgnQauF9sf
Great thread by @lauren_henke on GU003 / hypofrac for post-prostatectomy RT 👇🏼
Remember for post-op RT, the target *includes* the critical neighboring organs. Can't dose escalate 🎯 w/o ⬆️ dose to bladder neck and rectum @piet_ost@alison_tree@PaulSargos#ASTRO26@ASTRO_org
Honoured to co-host Prostate SBRT 2.0 with @DocJarad and @alison_tree@ASTRO_org#ASTRO26
Many pearls shared… one of the most important: baseline urinary function is key
#ASTRO26 Discussant @Sophia_KamranMD
What to do in the clinic tomorrow with PAM50?
Updated recommendations after NRG Oncology-RTOG 0534 Analysis 👇
@urotoday
Programming in the #ASTRO26 communities lounge is 🔥🔥🔥 join us for amazing discussions and also a place to take a break and relax. The @ASTRO_org communities lounge is halfway down the 101-109 hallway on the first floor!
Presented our @ARRO_org-jDEGRO survey at #ASTRO26: only 20% of U.S. trainees had rotation exposure to nonmalignant RT, and 65% saw just 0-10 cases during residency. Yet 95.8% supported including training for non malignant RT in core residency training. #RadOnc#MedEd@ASTRO_org
Excellent point! That’s why in our phase 1 GCC2048 study we had a beautiful and interesting trial design.
You want to know more?
Visit our poster presentation Tuesday 2:15-3:30 screen 11 at #ASTRO26 to talk about #prostatecancer work done by @UMarylandRadOnc